HealthMed Services, Ltd. to Expand Portfolio of Products Beyond Organ Transplantation
March 21 2012 - 8:30AM
Marketwired
HealthMed Services, Ltd. (PINKSHEETS: HEME) -- Dr. Henry J. Smith,
President of HealthMed Services, Ltd., stated today that "Our
business plan is to expand our portfolio of products beyond organ
transplantation, to include promising new technologies that can be
commercialized within a fairly short period of time."
Dr. Smith added, "In the field of Diabetes Testing the Company
has developed a saliva test for monitoring glucose control in
diabetes. Diabetics will be able to mail a saliva sample to a
laboratory that will perform the test and record the result.
Patients will be able to access their results in private using the
Internet."
Dr. Smith further stated, "The acquisition and merger of
Diabetes Reference Services last year gave us the enabling
technologies to monitor glucose control in Type 2 diabetics in a
non-invasive manner by testing saliva samples. This technology
represents an important component of any diabetes prevention
program. The medical profession cannot ignore that there is a
diabetes epidemic occurring throughout the world and the medical
and economic effects will be catastrophic if it is not recognized.
However, with timely testing, counseling and simple life-style
changes such as dieting and exercise, the onset of diabetes can be
mitigated or prevented. The routine saliva testing under
development by HealthMed Services to monitor glucose control is
simple, convenient and painless, and we believe it will encourage
compliance with all diabetes prevention programs."
About HealthMed Services, Ltd.
HealthMed Services, Ltd. has acquired the intellectual property
rights to two important medical technologies. In the field of Organ
Transplantation, the Company is developing a device for keeping
isolated donor organs alive for extended periods of time outside
the body. This will allow the donor organ to be transported across
the country to allow better donor and patient matching. Also the
better the donor organ can be preserved the better will be the
outcome of the organ transplantation. In the field of Diabetes
Testing, the Company has developed a saliva test for monitoring
glucose control in diabetes. Diabetics will be able to mail a
saliva sample to a laboratory that will perform the test and record
the result. Patients will be able to access their results in
private using the Internet.
Notice Regarding Forward-Looking
Statements
This news release contains "forward-looking statements," as that
term is defined in Section 27A of the United States Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Statements in this press release which are not purely historical
are forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future.
Such forward-looking statements include, among other things, the
development, costs and results of our exploration program at our
properties and any anticipated future production. Actual results
could differ from those projected in any forward-looking statements
due to numerous factors. Such factors include, among others, the
inherent uncertainties associated with cleaning fluid and
development stage exploration companies. These forward-looking
statements are made as of the date of this news release, and we
assume no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
projected in the forward-looking statements. Although we believe
that the beliefs, plans, expectations and intentions contained in
this press release are reasonable, there can be no assurance that
such beliefs, plans, expectations or intentions will prove to be
accurate. Investors should consult all of the information set forth
herein and should also refer to the risk factors disclosure
outlined in our annual report, quarterly reports or current reports
filed from time-to-time with OTC Markets, Inc.
Contact: Richard E. Floegel (619) 248-6868
Healthmed Services (PK) (USOTC:HEME)
Historical Stock Chart
From Apr 2024 to May 2024
Healthmed Services (PK) (USOTC:HEME)
Historical Stock Chart
From May 2023 to May 2024